Medtronic Secures Sinus Surgery Clearance and Reimbursement Codes as MiniMed Separation Nears Completion
Published on 10/11/2026 at 14:51 | Editorial boerse-global.de
Medtronic's surgical navigation franchise picked up fresh momentum this week, with U.S. regulators clearing the company's ApexCut EM navigated blades for sinus procedures. The 510(k) authorization, granted Wednesday, covers an instrument designed to pair with the Stealth AXiS ENT navigation platform, linking powered cutting tools to real-time imaging guidance during endoscopic work.
Management expects the first U.S. clinical cases to follow a scheduled software update later in 2026. The clearance deepens Medtronic's hand in ENT surgery, a field where precise imaging and navigation increasingly shape how complex operations are planned and executed.
R&D Spending Tops $2.9 Billion as Pipeline Churns
The new device slots into a broader pattern of steady product renewal. In its Impact Report for fiscal 2026, released Tuesday, Medtronic disclosed that it poured $2.9 billion into research and development over the year. That spending translated into more than 315 product approvals across key markets, while the company says its technologies reached over 82 million patients globally.
Such a cadence of clearances underpins the company's operating story at a time when it is simultaneously reshaping its corporate structure. The exchange offer tied to the MiniMed separation ran its course on schedule, with the deadline set at October 9.
Should investors sell immediately? Or is it worth buying Medtronic?
Swap Ratio Fixed at 4.5939 Shares
Under the final terms, each accepted Medtronic share converts into 4.5939 MiniMed shares, capped at a maximum of 225,361,295 MiniMed shares. The transaction marks one of the more consequential portfolio moves in the company's recent history, sharpening its focus on core segments.
Reimbursement, meanwhile, is moving in Medtronic's favor on several fronts. The American Medical Association has granted Category I CPT codes for both the Altaviva and Symplicity Spyral systems, a decision the company announced October 1. Those billing codes take effect in January 2028, paving the way for standardized reimbursement of the associated procedures once they go live.
Clinical Data Piles Up Across Vascular and Urology Programs
Evidence generation continues in parallel. On October 3, Medtronic unveiled prospective global clinical data from its VenaSeal Spectrum Program, covering treatment of advanced chronic venous disease. The results add scientific ballast to a portfolio aimed at vascular conditions, where clinical proof is the currency that drives payer coverage and physician adoption. VenaSeal itself ranks among the established interventional approaches to vein treatment, with ongoing study programs steadily refining where it fits.
Urology is advancing too. Medtronic presented exploratory 24-month results from the TITAN-2 study of its Altaviva system on Tuesday, and named Ariana L. Smith as national principal investigator for the follow-on ENDURANCE post-approval trial.
Leadership Shift in Cardiac Ablation
Personnel changes accompanied the clinical and regulatory news. Felicia Kurz was appointed vice president and general manager of the Cardiac Ablation Solutions division, a role that puts her at the helm of one of the company's key growth bets.
Medtronic at a turning point? This analysis reveals what investors need to know now.
Citi Stays Bullish With $110 Target
Analysts remain constructive on the stock. Joanne Wuensch of Citi reiterated her "Buy" rating on Monday, keeping a price target of $110. Shares finished Friday's session at EUR 79.00, a gain of 1.0% on the day, giving Medtronic a market capitalization of EUR 100.18 billion. The stock had drawn attention just over a week earlier when new billing codes for spinal cord and renal treatments caught the eye of market participants.
Taken together — clinical readouts, regulatory green lights, reimbursement wins and portfolio pruning — the company is pressing ahead with a strategy centered on its core therapeutic areas.
Ad
Medtronic Stock: New Analysis - 11 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
